secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-08-03T11:41:33+00:00
Accession:  0001140361-26-030568
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma reports positive safety data from first 3 patients in Phase 2 Danon disease trial
--------------------------------------------------------------------------------

- Initial three patients treated safely with RP-A501 at recalibrated dose 3.8×10^13 GC/kg; no TMA or capillary leak syndrome observed.
- Company engaging with FDA to align on path to complete pivotal Phase 2 trial; regulatory update expected H2 2026.
- Comprehensive Danon disease program update on track for H2 2026.
- Phase 2 trial designed as 12-patient single-arm study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/0001140361-26-030568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/ef20079241_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-030568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer